Newsroom
Sorted by: Latest
-
Cintas Corporation annonce ses résultats financiers du premier trimestre 2027
CINCINNATI--(BUSINESS WIRE)--Cintas Corporation (Nasdaq : CTAS) publie ce jour les résultats de son premier trimestre 2027 terminé le 31 août 2026. Le revenu du premier trimestre 2027 s'est établi à 3,01 milliards de dollars, contre 2,72 milliards de dollars au premier trimestre de l'exercice précédent, soit une hausse de 10,9%. Le taux de croissance organique du revenu pour le premier trimestre 2027, qui tient compte de l'incidence des acquisitions, des fluctuations des taux de change et des d...
-
U.S. Trademark “BEtreat” Owned by Mondiwell Founder
CONCORD, Mass.--(BUSINESS WIRE)--BEtreat (R) is a U.S. trademark held by the founder of Mondiwell, a provider of nature-based wellness, mindful writing and equine connection offerings...
-
Holiday Hosting, Handled! Dickey’s Canada Debuts Complete Holiday Feasts for Large Parties
OTTAWA, Ontario--(BUSINESS WIRE)--Dickey’s Barbecue Pit is bringing the heat to holiday tables across Canada with the launch of all-encompassing holiday menu, designed to make hosting easier and give fans a one pit stop for all their holiday hosting needs. Featuring slow-smoked meats, homestyle sides and classic seasonal favorites, the limited-time lineup offers a Texas-inspired twist on traditional holiday meals. Available for a limited time at participating locations across Canada, the holida...
-
INVST Named a Proud Partner of Indiana University Athletics
INDIANAPOLIS--(BUSINESS WIRE)--INVST, LLC (“INVST”) announced its multi-year paid sponsorship agreement to act as a Proud Sponsorship Partner of Indiana University Athletics....
-
Countable Labs Sets a New Standard in Molecular Testing for Hematologic Malignancy Clinical Applications
PALO ALTO, Calif.--(BUSINESS WIRE)--Countable Labs announces Ancora assays for molecular testing of hematologic malignancy, marking the company's entry into clinical markets....
-
Aelis Farma: Availability of the 2026 Half-Year Financial Report
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces that its 2026 half-year financial report has been made available to the public and filed with the French Financial Markets Authority (Autorité des marchés financiers). It can be consulted on the Company's website, www.aelisfarma.c...
-
South 8 Begins Volume Production of Extreme Cold Weather Lithium-Ion Batteries for Defense Customers
SAN DIEGO--(BUSINESS WIRE)--South 8 Technologies’ new semi-automated battery cell manufacturing line is now operational, marking a significant milestone in growing US domestic cell manufacturing capacity. The line will support 5 MWh of annual cylindrical cell production in 2027, enhancing South 8’s ability to serve defense and specialty markets requiring reliable battery performance in extreme cold. The manufacturing expansion supports production of South 8’s ARCTIC™ AE35 18650 cell, which uses...
-
Mesa Quantum Raises Oversubscribed $11.8 Million Round to End Dependence on Fragile GPS
BOULDER, Colo.--(BUSINESS WIRE)--Mesa Quantum, the company developing the next generation of quantum sensing technology for integration at scale, today announced it has raised $11.8 million in funding led by Playground Global. The round accelerates the company’s transition from component-level development to the full system integration and scaled production of deployable quantum timing and navigation units. Mesa Quantum is working to address a foundational vulnerability: the global dependence o...
-
Terminal Releases 2026 State of Remote Engineering Report, Revealing AI Fluent Engineers Face Rising Burnout and Retention Risk
SAN FRANCISCO--(BUSINESS WIRE)--New research reveals a workforce that has gone all in on AI, even as burnout climbs and retention risk grows for global engineering teams....
-
ADOCIA publie ses résultats financiers du premier semestre 2026 et dresse un bilan de ses activités
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC, la « Société »), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et de l’obésité, publie ses résultats financiers pour le premier semestre 2026 et fait le point sur ses activités. Les comptes semestriels consolidés de la Société aux normes IFRS ont fait l’objet d’une revue limitée par les...